Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Current Assets for 16 consecutive years, with $917.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets changed N/A to $917.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $917.0 million, a N/A change, with the full-year FY2025 number at $917.0 million, changed N/A from a year prior.
  • Current Assets was $917.0 million for Q4 2025 at Cytokinetics, down from $977.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.1 billion in Q2 2024 to a low of $364.2 million in Q2 2021.
  • A 5-year average of $718.5 million and a median of $638.7 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 91.7% in 2021, then plummeted 36.51% in 2023.
  • Cytokinetics' Current Assets stood at $535.7 million in 2021, then soared by 48.45% to $795.2 million in 2022, then fell by 21.02% to $628.1 million in 2023, then surged by 62.18% to $1.0 billion in 2024, then dropped by 9.98% to $917.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Current Assets are $917.0 million (Q4 2025), $977.3 million (Q3 2025), and $886.5 million (Q2 2025).